Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxinshi Tablet in Chronic Coronary Syndrome (YESTART)
ChiCTR2300077227Phase 4Recruiting
- Sponsor
- Shandong First Medical University
- Start
- Aug 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of yangxinshi in Chronic Coronary Syndrome (CCS) (2 arms), sponsored by Shandong First Medical University. Primary endpoint: 6-minute walk test distance (6MWT). Started Aug 2023; status: recruiting.
02
Drugs
yangxinshi
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on ChiCTR2300077227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077227.